FDA Approves Myqorzo for Symptomatic Obstructive Hypertrophic Cardiomyopathy

MONDAY, Jan. 5, 2026-- The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).Myqorzo is a cardiac myosin inhibitor that directly addresses...